Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
17 hedge funds and large institutions have $2.13M invested in Acorda Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 0 closing their positions.
13% more funds holding
Funds holding: 15 → 17 (+2)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
9% less capital invested
Capital invested by funds: $2.35M → $2.13M (-$212K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$123K |
| 2 |
Renaissance Technologies
New York
|
+$14.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.49K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$131 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$17.6K |
| 2 |
BlackRock
New York
|
-$7.56K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.79K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$73 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DKCM
1
Davidson Kempner Capital Management
New York
| $689K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $618K | +$14.5K | +1,000 | +2% |
|
3
Acadian Asset Management
Boston,
Massachusetts
| $420K | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $254K | +$123K | +8,452 | +78% |
|
|
5
BlackRock
New York
| $80.7K | -$7.56K | -521 | -8% |
|
|
6
Wells Fargo
San Francisco,
California
| $49.4K | -$73 | -5 | -0.1% |
|
|
7
Morgan Stanley
New York
| $15K | -$17.6K | -1,215 | -52% |
|
8
Russell Investments Group
London,
United Kingdom
| $3.75K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $1.4K | -$2.79K | -192 | -64% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1.36K | +$1.49K | +103 | New |
|
|
11
Bank of America
Charlotte,
North Carolina
| $674 | +$15 | +1 | +2% |
|
|
12
Fidelity Investments
Boston,
Massachusetts
| $114 | +$131 | +9 | New |
|
13
JP Morgan Chase
New York
| $50 | +$15 | +1 | +33% |
|
14
First Manhattan
New York
| $39 | – | – | – |
|
15
Osaic Holdings
Scottsdale,
Arizona
| $13 | – | – | – |
|
16
Qube Research & Technologies (QRT)
London,
United Kingdom
| $13 | – | – | – |
|
ACOR Hedge Fund Activity: Q1 2024 in Review
17 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2024, worth a combined $2.13M — down 9% from $2.35M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ACOR positions and 0 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $123K. The largest seller was Morgan Stanley, cutting an estimated $17.6K.
- 17 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2024, up from 15 in Q4 2023.
- Funds reported $2.13M of Acorda Therapeutics stock for Q1 2024, down 9% quarter-over-quarter.
- 2 funds opened new Acorda Therapeutics positions in Q1 2024 and 0 closed out, a net change of +2 holders.
- The largest Acorda Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $123K added.
- The largest Acorda Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $17.6K sold.
Based on aggregated 13F filings for Q1 2024.